CAJ | 학술논문

目的探讨进展期肺癌患者血浆D-二聚体水平与化疗疗效的关系.方法检测59例进展期肺癌患者[39例非小细胞肺癌(NSCLC),20例小细胞肺癌(SCLC)]化疗前、3个疗程化疗后及30例健康对照组的血浆D-二聚体含量.结果进展期肺癌患者化疗前血浆D-二聚体水平显著高于正常人(P＜0.01),且NSCLC组与SCLC组差异有显著性,D-二聚体在NSCLC组更高表达.NSCLC与SCLC患者的Ⅲ、Ⅳ期血浆D-二聚体水平均差异有显著性.39例进展期NSCLC患者化疗后有效(PR/CR)组D-二聚体含量为(223.00±102.16)mg/L,显著低于化疗前(P＜0.01),化疗后稳定(SD)组与化疗前相比差异无显著性(P=0.78),化疗后进展(PD)组D-二聚体含量是(1024.81±577.08)mg/L,明显高于化疗前(P＜0.01).SCLC患者中化疗后PR/CR和PD患者血浆D-二聚体水平与化疗前比较差异无显著性.结论血浆D-二聚体的水平高低可作为进展期肺癌观察病情、判断预后、观察疗效的一个指标,对NSCLC尤其适合.
목적 탐토진전기폐암환자혈장D-이취체수평여화료료효적관계.방법 검측59례진전기폐암환자[39례비소세포폐암(NSCLC),20례소세포폐암(SCLC)]화료전、3개료정화료후급30례건강대조조적혈장D-이취체함량.결과 진전기폐암환자화료전혈장D-이취체수평현저고우정상인(P＜0.01),차NSCLC조여SCLC조차이유현저성,D-이취체재NSCLC조경고표체.NSCLC여SCLC환자적Ⅲ、Ⅳ기혈장D-이취체수평균차이유현저성.39례진전기NSCLC환자화료후유효(PR/CR)조D-이취체함량위(223.00±102.16)mg/L,현저저우화료전(P＜0.01),화료후은정(SD)조여화료전상비차이무현저성(P=0.78),화료후진전(PD)조D-이취체함량시(1024.81±577.08)mg/L,명현고우화료전(P＜0.01).SCLC환자중화료후PR/CR화PD환자혈장D-이취체수평여화료전비교차이무현저성.결론 혈장D-이취체적수평고저가작위진전기폐암관찰병정、판단예후、관찰료효적일개지표,대NSCLC우기괄합.
Objective To evaluate the association and predictive value of D-dimer levels with chemotherapy response in advanced-stage lung cancer patients. Methods 59 patients and 30 healthy persons were evaluated and analysed; 39 patients had non-small-cell lung cancer (NSCLC) and 20 small-cell lung cancer (SCLC) and all were at an advanced stage. D-dimer levels were measured before and after 3 cycles of combination chemotherapy. D-dimer was measured with Latest method in SAGO STA-Compact Automatic analyzer. Results The level of D-dimer in 59 advanced-stage lung cancer patients was significantly higher than that of normal control (P＜0.01). Not only NSCLC cases but also SCLC patients,D-dimer levels were significantly different between Ⅲ and Ⅳ stage lung cancer. After chemotherapy, the level of D-dimer in NSCLC patients with PR/CR was markedly reduced (P＜0.01), but increased (P＜0.01) in PD cases, and not changed in SD patients. But, we found there were no significant difference in Ddimer plasma levels of SCLC cases for both PR/CR cases and PD patients. Conclusion D-dimer plasma levels decrease or increase after response and progressive disease, respectively. It can act as a predictive factor of the evolution of progressive disease with lung cancer, especially for NSCLC.